Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy

  title={Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy},
  author={Birte Hellwig and Katrin Madjar and Karolina Edlund and Rosemarie Marchan and Cristina Cadenas and Anne-Sophie Heimes and Katrin Almstedt and Antje Lebrecht and Isabel Sicking and Marco J. Battista and Patrick Micke and Marcus Schmidt and Jan G. Hengstler and J{\"o}rg Rahnenf{\"u}hrer},
  journal={PLoS ONE},
Background In breast cancer, gene signatures that predict the risk of metastasis after surgical tumor resection are mainly indicative of early events. The purpose of this study was to identify genes linked to metastatic recurrence more than three years after surgery. Methods Affymetrix HG U133A and Plus 2.0 array datasets with information on metastasis-free, disease-free or overall survival were accessed via public repositories. Time restricted Cox regression models were used to identify genes… 

Figures and Tables from this paper

BAIAP2L1 accelerates breast cancer progression and chemoresistance by activating AKT signaling through binding with ribosomal protein L3

The results indicated that BAIAP2L1 promotes breast cancer progression through the AKT signaling pathway by interacting with RPL3 through its SH3 domain.

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer

The current study of Axelrod et al. (2020) is of high interest, because the authors systematically analyzed tumor tissue before and after chemotherapy and clearly demonstrated the prognostic role of genes associated with better response.

EPN3 plays oncogenic role in non‐small cell lung cancer by activating the JAK1 / 2‐STAT3 pathway

EPN3 was abnormally up-regulated in NSCLC patients and cells, indicating a lower overall survival, and may be a promising target for NSClC treatment.

Ribosomal protein L5 (RPL5)/ E2F transcription factor 1 (E2F1) signaling suppresses breast cancer progression via regulating endoplasmic reticulum stress and autophagy

It is suggested that RPL5 has a tumor-suppressive effect in breast cancer by modulating ERS and autophagy via the regulation of E2F1.

Role of WDR5 in breast cancer prognosis

It is reported that downregulation of WDR5 by shRNA in breast cancer cells antagonizes the epithelial-to-mesenchymal transition through re-differentiation and reduces metastasis in a mouse model, and that targeting the WDR 5-TGFβ axis by a small molecular inhibitor reduces the migratory potential of breast cancers cells.

Weighted Cox regression for the prediction of heterogeneous patient subgroups

A penalized Cox regression model with a weighted version of the Cox partial likelihood that includes patients of all subgroups but assigns them individual weights based on their subgroup affiliation is proposed.

Tumor suppressor role of genes involved in circadian clock control

This study confirms previous studies presenting evidence for a tumor suppressor role of the circadian clock and the mechanisms of their tumor suppressive effect still need to be elucidated.

Circadian clocks in breast cancer

Broadberry E, McConell J, Williams J, Yang N, Zindy E, Leek A, Waddington R, Joseph L, Howe M, Meng QJ, Streuli CH (2018) Disrupted circadian clocks and altered tissue mechanics in primary human

Highlight report: Intratumoral metabolomic heterogeneity of breast cancer

The study shows that despite the intratumoral heterogeneity the analysis of only one or few replicates per tumor can be justified, when large cohorts of patients have to be analyzed.

Anticancer activity of luteolin glycosides

It is demonstrated that luteolin inhibited migration and invasion of MDA-MB-231 cells stimulated with the tumor promoter 12-O-tetradecanoylphorbol-3-acetate already at a non-cytotoxic concentration of 5 μM (Lee et al., 2019).

The humoral immune system has a key prognostic impact in node-negative breast cancer.

It is shown in three cohorts of untreated, node-negative breast cancer patients that the humoral immune system plays a pivotal role in metastasis-free survival of carcinomas of the breast.

Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

The prognostic sustainability of BCI to assess early- and late-distant recurrence risk at diagnosis has clinical use for decisions of chemotherapy at diagnosis and for decisions for extended adjuvant endocrine therapy beyond five years.

A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer

The combination of MGI and HOXB13:IL17BR outperforms either alone or alone and identifies a subgroup of early stage estrogen receptor–positive breast cancer patients with very poor outcome despite endocrine therapy.

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

  • J. CuzickM. Dowsett J. Forbes
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
The amount of prognostic information contained in four widely performed IHC assays is similar to that in the GHI-RS, which confirmed earlier reports that the mRNA-based, 21-gene Genomic Health recurrence score provided additional prognosis information regarding distant recurrence beyond that obtained from classical clinicopathologic factors.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.

A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors

IGKC was consistently associated with metastasis-free survival across different molecular subtypes in node-negative breast cancer and predicted response to anthracycline-based neoadjuvant chemotherapy and was prognostic in NSCLC and colorectal cancer.

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

None of the IHC4 markers provided statistically significant prognostic information in years 5 to 10, except for nodal status and tumor size, which may help select patients who could benefit most from hormonal therapy beyond 5 years of treatment.